Rejuvenate Biomed has completed enrollment for a Phase 2 trial of RJx-01, a multi-pathway therapeutic targeting mitochondrial dysfunction and neuromuscular impairment in COPD-related muscle loss. Early Phase 1b data indicated improvements in muscle strength and fatigue resistance, with results expected by end of 2026.
Key Points
- RJx-01 addresses four pathways: mitochondrial dysfunction, inflammation, fibrosis, neuromuscular imp
- Phase 1b showed gains in strength, function, and fatigue resistance with acceptable safety
- COPD-related sarcopenia currently lacks approved pharmacologic treatment options
Longevity Analysis
COPD-induced sarcopenia represents a convergence of energy production failure, inflammatory cascade, and structural decline—three core mechanisms that accelerate aging and functional loss in older adults. A drug targeting mitochondrial function alongside neuromuscular and inflammatory pathways directly addresses the root causes rather than symptoms, which is particularly significant given that muscle loss drives dependency, mortality risk, and systemic deconditioning in this population. Success in this trial would establish proof of concept for multi-system therapeutic intervention in a disease that currently offers no pharmacologic option to arrest or reverse muscle wasting.
Original published by LT Wire.